

U.S. Serial No. 09/528,225



**EXHIBIT A**

**COPY OF RESPONSE TO OFFICE ACTION DATED 06 NOVEMBER 2001 AND  
CERTIFICATE OF FIRST CLASS MAILING**



Docket No. 21

RECEIVED

SEP 20 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wang  
Serial No: 09/528,225  
Filed: March 21, 2000  
For: Chimeric Proteins For Diagnosis And Treatment Of Diabetes

Examiner: Saoud, C.  
Group: 1647

Assistant Commissioner for Patents  
Washington, D.C. 20231


CERTIFICATE OF MAILING

Date of Deposit: November 20, 2001

I hereby certify that the following:

- ☒ This Certificate of Mailing
- ☒ Response to Restriction Requirement
- ☒ Return postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

  
Carolynn Wise

Mark Farber  
C/O  
Alexion Pharmaceuticals, Inc.  
352 Knotter Drive  
Cheshire, CT 06419



RECEIVED

SEP 20 2002

TECH CENTER 1600/2900

DOCKET NO: 21

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Wang

Serial No.: 09/528,225

Examiner: Saoud, C.

Filed: March 21, 2000

Group: 1647

For: **Chimeric Proteins For Diagnosis And Treatment Of Diabetes**

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

RESPONSE

Sir:

In response to the Office Action mailed November 6, 2001 in connection with the above referenced application, please consider the following remarks.

REMARKS


Applicants elect to prosecute the claims of group 1, claims 1-15.

Despite the election, applicants traverse the restriction requirement. It is respectfully submitted that the Examiner should reconsider is the election of species requirement in view of the fact that the separate classification of the subject matter under the classification system of the United States Patent and Trademark Office is not conclusive proof of divisibility and further that the entire application must be examined as a whole when there would not be a serious burden on the Examiner. The fields of search are believed to be co-extensive for the three groups identified by the Examiner.

The Examiner is invited to contact the undersigned should he believe this would expedite prosecution of this application.

Respectfully submitted,

Date: 11/19/01




Mark Farber  
Attorney for Applicants  
Reg. No. 34, 159

Mark Farber  
Alexion Pharmaceuticals, Inc.  
352 Knotter Drive  
Cheshire, CT 06410



Law Offices

Mark Farber



SUITE 400 • SIX LANDMARK SQUARE • STAMFORD • CONNECTICUT • 06901 • 203-359-5752 • 203-359-5858

109488.135451

TELECOMMUNICATIONS INFORMATION PAGE

RECEIVED

DATE: July 23, 2002 SEP 20 2002  
PLEASE DELIVER THE FOLLOWING TO: Tamera Pertmer TECH CENTER 1600/2900  
AREA CODE AND TELECOPY NUMBER: (202) 942-8484  
AREA CODE AND TELEPHONE NUMBER: (202) 942-8400  
FROM: Mark Farber  
TOTAL PAGES INCLUDING THIS PAGE: 2  
COMMENTS:

*This message is intended for the use of the individual of entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone for directions to return the original material via the U.S. Postal Service.*

*Thank you*

DISTRIBUTED TO  
DISTRIBUTED TO

~~SPEARS/DOCKETING~~